Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Brief description of study
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo).
Detailed description of study
Additional Information
Male and Female
Age 18 - 65
Alopecia Areata
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alopecia Areata,Alopecia
-
Age: Between 18 Years - 65 Years
-
Gender: All
Updated on
09 Mar 2024.
Study ID: 849929
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
